Short Communication Open Access
Volume 2 | Issue 4 | DOI: https://doi.org/10.33696/cancerimmunol.2.026

Hepatocellular Carcinoma: Animal Models Available to Characterize Tumor Immunology and Optimize Treatment Development

  • 1Université Grenoble Alpes, France
  • 2Institute for Advanced Biosciences, Research Center UGA / Inserm U 1209 / CNRS 5309, Grenoble, France
  • 3Clinique Universitaire d’Hépato-gastroentérologie, Pôle Digidune, CHU Grenoble Alpes, France
+ Affiliations - Affiliations

Corresponding Author

Thomas Decaens, tdecaens@chu-grenoble.fr

Received Date: August 07, 2020

Accepted Date: August 27, 2020


Hepatocellular carcinoma is the second cause of cancer related-death worldwide with few therapeutic options. In this field, the rate of bench-to-bed translation of drugs is very modest, with 70% of drug attrition suggesting that preclinical evaluation should be urgently improved. Besides, recently immunotherapy showed very promising results and constitutes a real breakthrough in the area of HCC treatment. As these treatments aim to restore anti-tumor immunity, animal models including a functioning immune system are essential to allow a relevant preclinical validation. Macek Jilkova et al. describe, in a clear and forceful review which animal models can optimize this research and what are the pros and cons of each of them.


Hepatocellular carcinoma, Liver immunology, Animal models, Preclinical drug study

Author Information X